For the full presentation, downloadable slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/TQX865. CME/MOC/NCPD/AAPA credit will be available until January 27, 2026.
A Recap of Therapeutic Advances in HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer: Navigating the Latest Evidence and Maximizing Clinical Impact
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4.1
2525 ratings
For the full presentation, downloadable slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/TQX865. CME/MOC/NCPD/AAPA credit will be available until January 27, 2026.
A Recap of Therapeutic Advances in HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer: Navigating the Latest Evidence and Maximizing Clinical Impact
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Disclosure information is available at the beginning of the video presentation.
43,643 Listeners
137 Listeners
319 Listeners
702 Listeners
500 Listeners
28 Listeners
10 Listeners
1,382 Listeners
5 Listeners
10 Listeners
4 Listeners
2 Listeners
4 Listeners
2 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
2 Listeners
12 Listeners
2 Listeners
4 Listeners
3 Listeners
5 Listeners
289 Listeners
263 Listeners
3,341 Listeners
1,150 Listeners
191 Listeners
88 Listeners
514 Listeners
368 Listeners
431 Listeners